Journal of Neuro-Oncology

, Volume 88, Issue 1, pp 105–113 | Cite as

Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?

  • Amerigo BoiardiEmail author
  • Antonio Silvani
  • Marica Eoli
  • Elena Lamperti
  • Andrea Salmaggi
  • Paola Gaviani
  • Anna Fiumani
  • Andrea Botturi
  • Chiara Falcone
  • Alessandra Solari
  • Graziella Filippini
  • Francesco Di Meco
  • Giovanni Broggi
Clinical-Patient Studies


In this study, the records of 276 adult patients with recurrent glioblastoma (GBM) treated at recurrence at our institution between 2004 and 2006 were reviewed for progression-free survival (PFS), overall survival (OS), and toxicity. At recurrence, all patients underwent systemic treatment with temozolomide (200 mg/sqm on days 1–5 every 28 days) until tumor progression. Patients, whose tumor was judged resectable without risk of adjunctive neurological deficit, underwent a second surgery with or without positioning of a Rickam/Ommaya reservoir. The reservoir was used for locoregional chemotherapy with mitoxantrone. Two hundred seventy-six rGBL patients (pts) were divided into three subgroups: A 161 pts treated only with temozolomide, B 50 pts re-operated-on +temozolomide, and C 65 pts re-operated on + temozolomide + locoregional CHT. For group A, the 6 month PFS and 6 month survival (ST) were 39.3 and 43%, respectively, with a median survival time (mST) of 5 months (range 4–6) and 25% of pts alive at 9 months. For group B, the 6 month PFS and 6 month survivors were 64 and 74.1%, respectively, with a mST of 8 months (range 6–10) and 25% of pts alive at 12 months. For group C, the 6 month PFS and 6 month survivors were 70.7 and 87.7%, respectively, with a mST of 11 months (range 9–13) and 25% of pts alive at 18 months (A vs. B vs. C, log-rank P < 0.001) (B vs. C, P = 0.041) (A vs. B P = 0.009). Cox proportional hazard model was used to obtain Hazard Ratio (HR) for type of treatment corrected by age and time (in months) between diagnosis and first recurrence: second tumor debulking was statistically effective for survival, reducing by 36% the risk of death (HR = 0.64; 0.46–0.89), but the most significant favorable prognostic factor for survival was the local delivery of mitoxantrone which reduced the risk of death to 50% (HR = 0.50; 0.38–0.68).


Recurrent glioblastoma Ommaya reservoir Rickam Reservoir Mitoxantrone Locoregional chemotherapy 


  1. 1.
    Walker MD, Green SB, Byar DP et al (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323–1327PubMedCrossRefGoogle Scholar
  2. 2.
    Fine HA, Dear KBG, Loeffler YS et al (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71:2585–2597PubMedCrossRefGoogle Scholar
  3. 3.
    Tatter SB (2002) Recurrent malignant glioma in adults. Curr Treat Options Oncol 3:509–524PubMedCrossRefGoogle Scholar
  4. 4.
    Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRefGoogle Scholar
  5. 5.
    Esteller M, Hamilton SR, Burger PC et al (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793–797PubMedGoogle Scholar
  6. 6.
    Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003PubMedCrossRefGoogle Scholar
  7. 7.
    Huncharek M, Muscat J (1998) Treatment of recurrent high grade astrocytoma; results of a systematic review of 1415 patients. Anticancer Res 18:1303–1312PubMedGoogle Scholar
  8. 8.
    Yung WK, Albright RE, Olson J et al (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588–593PubMedCrossRefGoogle Scholar
  9. 9.
    Brada M, Hoang-Xuan K, Rampling R et al (2002) Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12:149–150Google Scholar
  10. 10.
    Dillman RO, Duma CM, Schiltz PM et al (2004) Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother 27:398–404PubMedCrossRefGoogle Scholar
  11. 11.
    Lidar Z, Mardor Y, Jonas T et al (2004) Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg 100:472–479PubMedGoogle Scholar
  12. 12.
    Chan TA, Weingart JD, Parisi M (2005) Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy. Int J Radiat Oncol Biol Phys 62:1133–1139PubMedGoogle Scholar
  13. 13.
    Di Meco F, Li KW, Tyler BM et al (2002) Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats. J Neurosurg 5:1173–1178Google Scholar
  14. 14.
    Brem H, Piantadossi S, Burger P et al (1995) Placebo controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lancet 345:1008–1012PubMedCrossRefGoogle Scholar
  15. 15.
    Westphal M, Ram Z, Riddle V et al (2006) On behalf of the executive committee of the Gliadel study group. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 148:269–275CrossRefGoogle Scholar
  16. 16.
    Westphal M, Hilt DC, Bortey E et al (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncology 5:79–88PubMedCrossRefGoogle Scholar
  17. 17.
    Senkal M, Tonn JC, Schonmayr R et al (1997) Mitoxantrone-induced DNA strand breaks in cell-cultures of malignant human astrocytoma and glioblastoma tumors. J Neurooncol 32:203–208PubMedCrossRefGoogle Scholar
  18. 18.
    Perego P, Boiardi A, Carenini N et al (1994) Characterisation of an established human malignant glioblastoma cell line and its response to conventional drugs. J Cancer Res Clin Oncol 120:585–592PubMedCrossRefGoogle Scholar
  19. 19.
    Nikkhah G, Tonn JC, Hoffmann O (1992) The MTT assay for chemosensitivity testing of human tumors of the central nervous system. Part II: evaluation of patient- and drug-specific variables. J Neurooncol 13:13–24PubMedCrossRefGoogle Scholar
  20. 20.
    Wolff JE, Trilling T, Molenkamp G, Egeler RM, Jurgens H (1999) Chemosensitivity of glioma cells in vitro: a meta analysis. J Cancer Res Clin Oncol 125:481–486PubMedCrossRefGoogle Scholar
  21. 21.
    Ferroli P, Broggi M, Franzini A et al (2006) Surgifoam and mitoxantrone in the glioblastoma multiforme postresection cavity: the first step of locoregional chemotherapy through an ad hoc-placed catheter: technical note. Neurosurgery 59:433–434CrossRefGoogle Scholar
  22. 22.
    Boiardi A, Eoli M, Salmaggi A et al (2005) A systemic temozolomide combined with loco-regional mitoxantrone in treating recurrent glioblastoma. J Neurooncol 75:215–220PubMedCrossRefGoogle Scholar
  23. 23.
    Boiardi A, Eoli M, Salmaggi A et al (2003) New approach in delivering chemotherapy: locoregional treatment for recurrent glioblastoma (rGBM). J Exp Clin Cancer Res 22:123–127PubMedGoogle Scholar
  24. 24.
    MacDonald DR, Cascino TL, Clifford S (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280PubMedGoogle Scholar
  25. 25.
    Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRefGoogle Scholar
  26. 26.
    Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 5:649–655PubMedCrossRefGoogle Scholar
  27. 27.
    Nieder C, Grosu AL, Molls M (2000) A comparison of treatment results for recurrent malignant gliomas. Cancer Treat Rev 26:397–409PubMedCrossRefGoogle Scholar
  28. 28.
    Osoba D, Brada M, Prados MD (2000) Effect of disease burden on health-related quality of life in patients with malignant gliomas. Neuro-Oncology 4:221–228CrossRefGoogle Scholar
  29. 29.
    Abrey LE (2005) Concomitant chemoradiotherapy followed by adjuvant temozolomide improves survival in glioblastoma multiforme. Curr Neurol Neurosci Rep 5:167–168PubMedCrossRefGoogle Scholar
  30. 30.
    Gaya A, Rees J, Greenstein A et al (2002) The use of temozolomide in recurrent malignant gliomas. Cancer Treat Rev 28:115–120PubMedCrossRefGoogle Scholar
  31. 31.
    Sipos L, Vitanovics D, Afra D (2001) Treatment of recidive malignant gliomas with temozolomide. Ann Oncol 12:259–266CrossRefGoogle Scholar
  32. 32.
    Sipos L, Vitanovics D, Afra D (2002) Treatment of recidive malignant gliomas with temozolomide. Orv Hetil 143(21):1201–1204PubMedGoogle Scholar
  33. 33.
    Sipos L, Afra D (1997) Re-operations of supratentorial anaplastic astrocytomas. Acta Neurochir (Wien) 139:99–104CrossRefGoogle Scholar
  34. 34.
    Hau P, Baumgart U, Pfeifer K et al (2003) Salvage therapy in patients with glioblastoma: is there any benefit? Cancer 98:2678–2686PubMedCrossRefGoogle Scholar
  35. 35.
    Soults CB, Canute GS, Ryken TC (1998) Evidence-based review of the role of reoperation in the management of malignant glioma. Neurosurg Focus 15:11–16Google Scholar
  36. 36.
    Guyotat J, Signorelli F, Frappaz D et al (2000) Is reoperation for recurrence of glioblastoma justified? Oncol Rep 7:899–904PubMedGoogle Scholar
  37. 37.
    Barker FG, Chang SM, Gutin PH et al (1998) Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 42:709–720PubMedCrossRefGoogle Scholar
  38. 38.
    Pinsker M, Lumenta C (2001) Experiences with reoperation on recurrent glioblastoma multiforme. Zentralbl Neurochir 62:43–47PubMedCrossRefGoogle Scholar
  39. 39.
    Ammirati M, Galicich JH, Arbit E (1987) Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 21:607–614PubMedCrossRefGoogle Scholar
  40. 40.
    Dirks P, Bernstein M, Muller PJ et al (1993) The value of reoperation for recurrent glioblastoma. Can J Surg 36:271–275PubMedGoogle Scholar
  41. 41.
    Gabayan AJ, Green SB, Sanan A et al (2006) GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis. Neurosurgery 59:821–826CrossRefGoogle Scholar
  42. 42.
    Combs SE, Thilmann C, Edler L (2005) Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 23:8863–8869PubMedCrossRefGoogle Scholar
  43. 43.
    Shrieve DC, Alexander E, Wen PY (1995) Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery 36:275–282PubMedCrossRefGoogle Scholar
  44. 44.
    Riva P, Franceschi G, Riva N et al (2000) Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach. Eur J Nucl Med 27:601–609PubMedCrossRefGoogle Scholar
  45. 45.
    Paganelli G, Bartolomei M, Ferrari M (2001) Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. Cancer Biother Radiopharm 16:227–235PubMedCrossRefGoogle Scholar
  46. 46.
    Akabani G, Reardon DA, Coleman RE et al (2005) Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. J Nucl Med 46:1042–1051PubMedGoogle Scholar
  47. 47.
    Hayes RL, Koslow M, Hiesiger EM (1995) Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 76:840–852PubMedCrossRefGoogle Scholar
  48. 48.
    Lawson HC, Sampath P, Bohan E et al (2007) Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience. J Neurooncol 83:61–70PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Amerigo Boiardi
    • 1
    Email author
  • Antonio Silvani
    • 1
  • Marica Eoli
    • 1
  • Elena Lamperti
    • 1
  • Andrea Salmaggi
    • 1
  • Paola Gaviani
    • 1
  • Anna Fiumani
    • 1
  • Andrea Botturi
    • 1
  • Chiara Falcone
    • 2
  • Alessandra Solari
    • 2
  • Graziella Filippini
    • 2
  • Francesco Di Meco
    • 3
  • Giovanni Broggi
    • 3
  1. 1.Department of Neuro-oncologyFondazione IRCSS Istituto Neurologico Carlo BestaMilanItaly
  2. 2.Unit of Neuro-epidemiologyFondazione IRCSS Istituto Neurologico Carlo BestaMilanItaly
  3. 3.Department of NeurosurgeryFondazione IRCSS Istituto Neurologico Carlo BestaMilanItaly

Personalised recommendations